Skip to main content
SpringerLink
Log in

Retardiertes Melatonin in der Behandlung der primären Insomnie

Prolonged-release melatonin for the treatment of primary insomnia. Review

  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Hintergrund: Bei der primären (nicht organischen) Insomnie findet sich oft eine Störung des Schlaf-Wach-Rhythmus. Eine Schlüsselrolle kommt dabei dem Schlafhormon Melatonin zu. Der Zusammenhang zwischen niedrigen Melatoninspiegeln und Schlafstörungen wurde in einer Vielzahl von Studien gezeigt. Retardiertes Melatonin ahmt die Wirkung der endogenen Melatoninsekretion als Taktgeber für die innere Uhr und die schlafanstoßende Wirkung nach. Als einziges retardiertes Melatoninpräparat ist in Deutschland Circadin® zugelassen.

Methode: Übersichtsarbeit

Ergebnisse und Schlussfolgerungen: Die Europäische Zulassung basiert auf den Ergebnissen klinischer Studien, in denen die Einnahme des retardierten Melatoninpräparats die Einschlafzeit verkürzte, die Schlafqualität ohne Veränderung der physiologischen Schlafarchitektur verbesserte und die Tagesleistungsfähigkeit versus Placebo erhöhte [2, 4, 5]. Dabei zeigte das retardierte Melatoninpräparat ein gutes Sicherheits- und Verträglichkeitsprofil.

Abstract

Background: In primary (non-organic) insomnia the sleep-wake rhythm often is out of order. A key role comes to the sleep hormone melatonin. The relationship between low melatonin levels and sleep disorders has been demonstrated in a variety of studies. Prolonged-release melatonin copies the effect of endogenous melatonin secretion as an internal clock and the sleep-inducing effect. The only prolonged-release melatonin preparation approved in Germany is Circadin®.

Method: Review

Results: The European approval was based on results of clinical trials, in which the intake of prolonged-release melatonin shortened time to fall asleep, improved quality of sleep without altering the physiological sleep architecture and increased next-day performance versus placebo. Prolonged-release melatonin showed to be safe and well tolerated.

Results and conclusions: The European approval was based on results of clinical trials, in which the intake of prolonged-release melatonin shortened time to fall asleep, improved quality of sleep without altering the physiological sleep architecture and increased next-day performance versus placebo. Prolonged-release melatonin showed to be safe and well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009; 24(5): 239–249.

    Article  PubMed  Google Scholar 

  2. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother 2012; 13(6): 895–905.

    Article  CAS  PubMed  Google Scholar 

  3. Fachinformation Circadin 2 mg Retardtabletten, Stand: August 2013.

  4. Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010; 8: 51.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Wade AG, Crawford G, Ford I, et al. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin 2011; 27(1): 87–98.

    Article  CAS  PubMed  Google Scholar 

  6. Kandel ER, Schwartz JH, Jessell TM (eds). Principles of neural science. McGraw-Hill, New York 2000.

    Google Scholar 

  7. Deutsches Institut für Medizinische Dokumentation und Information (DIMDI). Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10. Revision, German Modification (ICD-10-GM), 2015.

  8. Schwabe U, Paffrath D (Hrsg). Arzneiverordnungsreport 2013. Springer Verlag, Berlin Heidelberg 2013.

    Google Scholar 

  9. Zisapel N. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs 2001; 15(4): 311–328.

    Article  CAS  PubMed  Google Scholar 

  10. Panda S, Nayak SK, Campo B, Walker JR, Hogenesch JB, Jegla T. Illumination of the melanopsin signaling pathway. Science 2005; 307(5709): 600–604.

    Article  CAS  PubMed  Google Scholar 

  11. Hannibal J, Hindersson P, Ostergaard J, et al. Melanopsin is expressed in PACAP-containing retinal ganglion cells of the human retinohypothalamic tract. Invest Ophthalmol Vis Sci 2004; 45(11): 4202–4209.

    Article  PubMed  Google Scholar 

  12. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12(2): 151–180.

    Article  CAS  PubMed  Google Scholar 

  13. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005; 9(1): 25–39.

    Article  PubMed  Google Scholar 

  14. Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 2007; 21(12): 995–1018.

    Article  CAS  PubMed  Google Scholar 

  15. Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfat-oxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004; 116(2): 91–95.

    Article  CAS  PubMed  Google Scholar 

  16. Wu YH, Zhou JN, Van Heerikhuize J, Jockers R, Swaab DF. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer’s disease. Neurobiol Aging 2007; 28(8): 1239–1247.

    Article  CAS  PubMed  Google Scholar 

  17. Dawson D, Armstrong SM. Chronobiotics–drugs that shift rhythms. Pharmacol Ther 1996; 69: 15–36.

    Article  CAS  PubMed  Google Scholar 

  18. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007; 16(4): 372–380.

    Article  PubMed  Google Scholar 

  19. Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007; 23(10): 2597–2605.

    Article  CAS  PubMed  Google Scholar 

  20. Otmani S, Demazières A, Staner C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol 2008; 23(8): 693–705.

    Article  CAS  PubMed  Google Scholar 

  21. Lemoine P, Garfinkel D, Laudon M, Nir T, Zisapel N. Prolonged-release melatonin for insomnia–an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag 2011; 7: 301–311.

    PubMed Central  CAS  PubMed  Google Scholar 

  22. De Leersnyder H, Zisapel N, Laudon M. Prolonged-release melatonin for children with neurodevelopmental disorders. Pediatr Neurol 2011; 45(1): 23–26.

    Article  PubMed  Google Scholar 

  23. Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord 2006; 36(6): 741–752.

    Article  CAS  PubMed  Google Scholar 

  24. Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008; 44(1): 57–64.

    CAS  PubMed  Google Scholar 

  25. NHS–National Health Service (UK); Mai 2015. http://www.barkingdagenhamccg.nhs.uk/downloads/For-health-professionals/Medicines-management/Shared%20Care/Melatonin%20SCG%20for%20sleep%20disorder%20difficulties%20in%20children.pdf (zuletzt aufgerufen am 24.11.2015).

  26. Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes 2011; 4: 307–313.

    PubMed Central  CAS  PubMed  Google Scholar 

  27. Lemoine P, Wade AG, Katz A, Nir T, Zisapel N. Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. Integr Blood Press Control 2012; 5: 9–17.

    PubMed Central  CAS  PubMed  Google Scholar 

  28. Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging 2014; 9: 947–961.

    PubMed Central  CAS  PubMed  Google Scholar 

  29. Hajak G, Lemme K, Zisapel N. Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin. Int Clin Psychopharmacol 2015; 30(1): 36–42.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pastorenbusch 2, 48161, Münster, Deutschland

    Klaus Wahle (Arzt für Innere und Allgemeinmedizin, Hausarzt)

Authors
  1. Klaus Wahle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Wahle.

Additional information

This article is part of a supplement not sponsored by the industry.

Interessenkonflikt

Prof. Klaus Wahle ist für verschiedene pharmazeutische Unternehmen in Advisory Boards beratend tätig. Er erklärt, dass kein Interessenkonflikt in Bezug auf dieses Manuskript besteht.

Die Arbeit wurde unterstützt von der MEDICE Arzneimittel Pütter GmbH & Co. KG, Iserlohn.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wahle, K. Retardiertes Melatonin in der Behandlung der primären Insomnie. MMW - Fortschritte der Medizin 157 (Suppl 7), 14–18 (2015). https://doi.org/10.1007/s15006-015-7565-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-015-7565-2

Schlüsselwörter

Keywords

Search

Navigation